The molecular glue-breaking medication furthest in improvement are potential most cancers remedies, however Monte Rosa Therapeutics can also be exploring how this therapeutic modality might deal with immunological issues. Novartis sees promise in a Monte Rosa drug candidate designed to interrupt down a protein related to autoimmune ailments, and the pharmaceutical big is paying $150 million for the worldwide rights […]
